immune-checkpoint-inhibitor

Documents about immune-checkpoint-inhibitor

• Adjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular Carcinoma#835507ClinicalTrials.gov
• PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure#864722ClinicalTrials.gov
• Real World Pharmacokinetics of Immune Checkpoint Inhibitors#992775ClinicalTrials.gov
• Development of an EORTC Immune Checkpoint Inhibitor-specific Quality of Life Item List: Phase 1 & 2#28318ClinicalTrials.gov
• TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma#201713ClinicalTrials.gov
• Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC#811484ClinicalTrials.gov
• Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors#268893IRIS
• Vaccine safety for individuals receiving immune checkpoint inhibitor therapy: A narrative review of current literature and recommendations for future research#4645Europe PMC
• XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy#835520ClinicalTrials.gov
• Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)#889901ClinicalTrials.gov
• A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy#448275ClinicalTrials.gov
• Artificial intelligence in immune checkpoint inhibitor research: A bibliometric analysis of the landscape.#412895PubMed
• Comparative Efficacy of First-Line Immune Checkpoint Inhibitor-Based Combination Therapies in Patients With Sarcomatoid Renal Cell Carcinoma: A Japanese Multicenter Cohort Study#338818OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma#444870ClinicalTrials.gov
• Baseline D-dimer as a predictor of immune checkpoint inhibitor efficacy in cancer#4693Europe PMC
• Clinical Significance of Hepatic Biomarkers in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors#873179ClinicalTrials.gov
• Mycophenolate Mofetil w/ Prednisone for Immune Related Hepatitis From Checkpoint Inhibitor Therapy#332755ClinicalTrials.gov
• Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial#460102ClinicalTrials.gov
• Checkpoint inhibitor effectiveness after corticosteroids and second-line immunosuppressants for immune-related adverse events in non-small-cell lung cancer#374506HAL (France)
• Association Of Immune Checkpoint Inhibitor Approval On Suicide Rates Among Patients With Cancer: A Pre-Post Analysis With Seer#167490EliScholar
• The Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors#875335ClinicalTrials.gov
• Immune checkpoint inhibitor-induced cardiotoxicity: from immune mechanisms to clinical surveillance and targeted therapies.#452937NCBI PubMed Central
• Autoimmune Endocrine Disease Related Antibodies Before the Start of Immune Checkpoint Inhibitor Therapy#460093ClinicalTrials.gov
• Combination of TATE and PD-1 Inhibitor in Liver Cancer#912261ClinicalTrials.gov
• Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer#907966ClinicalTrials.gov
• Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature#893644ClinicalTrials.gov
• Pilot Study of Intermittent Fasting With Immune Checkpoint Inhibitors#881858ClinicalTrials.gov
• Antibiotic Timing and Survival After Immune Checkpoint Inhibitor Initiation in Patients With Cancer#314177bioRxiv / medRxiv
• Neutrophil-to-lymphocyte ratio affects the impact of proton pump inhibitors on efficacy of immune checkpoint inhibitors in patients with non‑small-cell lung cancer#194772OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• B-Cell involvement in immune checkpoint inhibitor-induced lichen planus: A comparative analysis with non–drug-related lichen planus#471876HAL (France)
• Immune Checkpoint Inhibitor Associated Cardiovascular Adverse Events in Patients With Cancer#839698ClinicalTrials.gov
• Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment#830950ClinicalTrials.gov
• Modulating the gut microbiota to enhance immune checkpoint inhibitor efficacy in colorectal cancer: mechanisms, therapeutic strategies, and clinical perspectives#120190Europe PMC
• Natural polysaccharides as immune adjuvants to overcome immune checkpoint inhibitor resistance: mechanistic insights, clinical evidence, and translational challenges.#476858NCBI PubMed Central
• The efficacy of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: A meta-analysis and reconstructed individual patient data analysis#4635Europe PMC
• Urinary Chemokines in the Diagnosis and Monitoring of Immune Checkpoint Inhibitor-Associated Nephritis#184964Dipòsit Digital de la Universitat de Barcelona
• Immune checkpoint inhibitor neurotoxicity: long-term outcomes with focus on 1-year neurological sequelae#433385HAL (France)
• Remodeling memory T cells with chemotherapy and immune checkpoint inhibitors as host pre-conditioning to empower in vivo CAR-T therapy#253510Europe PMC
• Patients with Cancer and Immune Checkpoint Inhibitor-Induced Rheumatic irAEs Treated by DMARDs: The RHUMICI Single-Centre Retrospective Cohort#922929HAL (France)
• Ursodeoxycholic Acid Alone Is Effective and Safe to Treat Cholestatic Checkpoint Inhibitor‐Induced Liver Injury#280347HAL (France)
• Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer#274674IRIS
• Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis#346910ClinicalTrials.gov
• IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma#373618ClinicalTrials.gov
• Pharmacovigilance Evaluation of Noninfectious Myocarditis and Pericarditis in Immune Checkpoint Inhibitor Recipients Using FAERS.#404376NCBI PubMed Central
• CT-Based Deep Foundation Model for Predicting Immune Checkpoint Inhibitor-Induced Pneumonitis Risk in Lung Cancer#480179bioRxiv / medRxiv
• Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App#892494ClinicalTrials.gov
• Influence of oncogenic drivers and signaling pathways on immune checkpoint inhibitor efficacy in NSCLC#1015719Europe PMC
• Supplementary file 1_Immune checkpoint inhibitor-related myotoxicity in lung cancer: a decade-long real-world pharmacovigilance analysis of the FAERS database.docx#1038752Figshare
• Time-related biases in observational studies : an illustration with COVID-19 vaccination during immune checkpoint inhibitor therapy#223942bioRxiv / medRxiv
• Study Protocol to Characterize Symptom Experience During Immune Checkpoint Inhibitor Therapy for Cutaneous Melanoma.#389015NCBI PubMed Central